Full-Life Technologies Reports First-in-Human Imaging Data for c-MET-Targeting Theranostic Ligand FL-261 Showing Robust Tumor Uptake, High Lesion Contrast and No Tracer-Related Serious Adverse Events in Patients with NSCLC

Data ReadoutpositiveFL-261Positive

AI Analysis

Summary

Full-Life Technologies reported first-in-human imaging data for its c-MET-targeting theranostic ligand FL-261 in 10 NSCLC patients, showing robust tumor uptake, high lesion contrast and no tracer-related serious adverse events. The data were featured as a Top Rated Oral Presentation at the 39th EANM Annual Congress.

Clinical Trial Data

Phase

Phase_1

Patients

Outcome Details

First-in-human imaging in 10 NSCLC patients showed robust tumor uptake, high lesion contrast and no tracer-related serious adverse events; presented as a Top Rated Oral Presentation at the 39th EANM Annual Congress.

Importance:4/10

Sentiment:

0.60

theranosticsc-METNSCLCradiopharmaceuticalimagingfirst-in-humanEANMoncology

Related Companies

$SHWZ $LGNYZ $TRAX

Read the original article

Published by PR Newswire Biotech on October 19, 2026 2:20 PM

Read Original